STAT3-IN-13

立即咨询

STAT3-IN-13

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	2248552-86-3
规格:	≥98%

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议

产品介绍

理化性质和储存条件

Molecular Formula: C21H20N6O3S;

Molecular Weight: 436.49

In Vitro	STAT3-IN-13 (compound 6f in the paper) (48 hours) has anti-proliferative activity with IC50 values of 0.25, 0.11 and 0.55 μM for 143B, HOS and MG63 cells, respectively[1]. STAT3-IN-13 (compound 6f) (0.001-100 μM) binds to STAT3 and interacts with STAT3586–685 in a concentration dependent manner with a KD of 0.96 μM[1]. STAT3-IN-13 (compound 6f) (0-1.0 μM; 24 hours; 143B and HOS cells) inhibits STAT3 Y705 phosphorylation and suppresses STAT3 in tumor cells[1]. STAT3-IN-13 (compound 6f) (0-1.0 μM; 48 hours; 143B cells) induces apoptosis in a dose-dependent manner[1]. Apoptosis Analysis[1] Cell Line: 143B cells Concentration: 0, 0.2, 0.5, and 1 μM Incubation Time: 48 hours Result: Increased the percentage of apoptosis rates of 3.4%, 8.7%, 10.7%, and 23.3% at 0, 0.2, 0.5 and 1 μM, respectively. Western Blot Analysis[1] Cell Line: 143B and HOS cells Concentration: 0, 0.2, 0.5 and 1.0 μM Incubation Time: 24 hours Result: Inhibited STAT3 Y705 phosphorylation and downstream target gene expression including Bcl-2 and VEGF, retained good antitumor activities against control tumor cells without STAT3 knockdown.
In Vivo	STAT3-IN-13 (10-20 mg/kg; i.p.; twice daily, for 4 weeks; nude mice) blocks osteosarcoma growth and metastasis in vivo[1]. Animal Model: Nude mice Dosage: 10 and 20 mg/kg Administration: Intraperitoneal injection; twice daily, for 4 weeks Result: Suppressed tumor weight at a dose of 10 mg/kg.

In Vitro

STAT3-IN-13 (compound 6f in the paper) (48 hours) has anti-proliferative activity with IC50 values of 0.25, 0.11 and 0.55 μM for 143B, HOS and MG63 cells, respectively[1]. STAT3-IN-13 (compound 6f) (0.001-100 μM) binds to STAT3 and interacts with STAT3586–685 in a concentration dependent manner with a KD of 0.96 μM[1]. STAT3-IN-13 (compound 6f) (0-1.0 μM; 24 hours; 143B and HOS cells) inhibits STAT3 Y705 phosphorylation and suppresses STAT3 in tumor cells[1]. STAT3-IN-13 (compound 6f) (0-1.0 μM; 48 hours; 143B cells) induces apoptosis in a dose-dependent manner[1]. Apoptosis Analysis[1] Cell Line: 143B cells Concentration: 0, 0.2, 0.5, and 1 μM Incubation Time: 48 hours Result: Increased the percentage of apoptosis rates of 3.4%, 8.7%, 10.7%, and 23.3% at 0, 0.2, 0.5 and 1 μM, respectively. Western Blot Analysis[1] Cell Line: 143B and HOS cells Concentration: 0, 0.2, 0.5 and 1.0 μM Incubation Time: 24 hours Result: Inhibited STAT3 Y705 phosphorylation and downstream target gene expression including Bcl-2 and VEGF, retained good antitumor activities against control tumor cells without STAT3 knockdown.

In Vivo

STAT3-IN-13 (10-20 mg/kg; i.p.; twice daily, for 4 weeks; nude mice) blocks osteosarcoma growth and metastasis in vivo[1]. Animal Model: Nude mice Dosage: 10 and 20 mg/kg Administration: Intraperitoneal injection; twice daily, for 4 weeks Result: Suppressed tumor weight at a dose of 10 mg/kg.